secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001682852-25-000073
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q3 net loss $200M, revenue $1.0B down 45% YoY; narrows 2025 guidance
----------------------------------------------------------------------------

- Q3 revenue $1.0B (down 45% YoY); net loss $(0.51)/share vs. EPS $0.03 in Q3 2024.
- 2025 revenue range narrowed to $1.6-2.0B; GAAP opex cut by $0.7B to $5.2-5.4B.
- Year-end cash target raised by $0.5-1.0B to $6.5-7.0B; Q3-end cash $6.6B.
- COVID vaccine sales $971M; RSV mRESVIA sales $2M; mNEXSPIKE launched in US.
- Discontinues congenital CMV program after Phase 3 missed primary endpoint; norovirus study extends.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285225000073/0001682852-25-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285225000073/mrna-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001682852-25-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer